Skip Navigation


Rheumatology Advance Access originally published online on November 23, 2004
Rheumatology 2005 44(3):271-273; doi:10.1093/rheumatology/keh483
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Rheumatology First Quarter 2005 Quiz
Right arrow All Versions of this Article:
44/3/271    most recent
keh483v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mpofu, S.
Right arrow Articles by Moots, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mpofu, S.
Right arrow Articles by Moots, R. J.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2004; all rights reserved

REVIEW

Anti-TNF-{alpha} therapies: they are all the same (aren't they?)

S. Mpofu, F. Fatima and R. J. Moots

Academic Rheumatology Unit, University of Liverpool, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK.

Correspondence to: R. J. Moots. E-mail: rjmoots@liv.ac.uk

The first 10% of the full text of this article appears below.

The development of anti-tumour necrosis factor {alpha} (TNF-{alpha}) therapy has been a milestone in the treatment of rheumatoid arthritis (RA) and is proving equally important in other inflammatory-mediated conditions [1–3]. The three currently licensed biological anti-TNF-{alpha} drugs, etanercept, infliximab and adalimumab, have all been clearly shown to suppress disease activity in RA. They all target the same molecule—but are they really just more of the same and, indeed, are all three needed? As uptake of anti-TNF-{alpha} therapy increases around the world, these questions are becoming increasingly posed. However, it is also becoming clear that these drugs possess significant differences, both in vitro and clinically. Understanding these differences is of course important for the clinic, but equally important is the appreciation that these . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
V. Strand, A. Balbir-Gurman, K. Pavelka, P. Emery, N. Li, M. Yin, P. B. Lehane, and S. Agarwal
Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years
Rheumatology, December 1, 2006; 45(12): 1505 - 1513.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Dziadzio, V. Reddy, S. Rahman, C. Mummery, and A. Keat
Is TNF{alpha} really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab
Rheumatology, November 1, 2006; 45(11): 1445 - 1446.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. Sheehy, E. Murphy, and M. Barry
Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy
Rheumatology, October 1, 2006; 45(10): 1314 - 1315.
[Full Text] [PDF]